Proactive Cardiovascular Risk Management versus Usual Care in Patients with and without Diabetes Mellitus: CRUCIAL Trial Subanalysis

References

• . Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14
   PubMed Web of Science ®Google Scholar
• . Adler AI, Neil HA, Manley SE, Holman RR, Turner RC. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). Am Heart J. 1999;138(5 pt 1): S353–S359
   PubMedGoogle Scholar
• . Preis SR, Pencina MJ, Hwang SJ, . Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation. 2009;120(3):212–220
   PubMed Web of Science ®Google Scholar
• . Skyler JS, Bergenstal R, Bonow RO, ; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119(2):351–357
   PubMed Web of Science ®Google Scholar
• . Grundy SM, Benjamin IJ, Burke GL, . Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100(10):1134–1146
   PubMed Web of Science ®Google Scholar
• . Zanella MT, Kohlmann O Jr, Ribeiro AB. Treatment of obesity hypertension and diabetes syndrome. Hypertension. 2001;38(3 pt 2):705–708
   PubMedGoogle Scholar
• . Fowler M. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82
   Google Scholar
• . Colhoun HM, Betteridge DJ, Durrington PN, ; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696
   PubMed Web of Science ®Google Scholar
• . Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005–2016
   PubMed Web of Science ®Google Scholar
• . Sever PS, Poulter NR, Dahlöf B, . Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOTLLA). Diabetes Care. 2005;28(5):1151–1157
   PubMed Web of Science ®Google Scholar
• . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703–713
   PubMed Web of Science ®Google Scholar
• . Gæde P, Lund—Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591
   PubMed Web of Science ®Google Scholar
• . Gæde P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393
   PubMed Web of Science ®Google Scholar
• . Neutel JM, Eaddy M, Lunacsek OE, . Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice. J Clin Hypertens. 2010;12(6):396–406
   Google Scholar
• . Wong ND, Lopez V, Tang S, Williams GR. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006;98(2):204–208
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Data, 1999–2006. http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm. Accessed December 14, 2010
   Google Scholar
• . Chen L, Mardekian J. Controlling hypertension and dyslipidemia to guideline-recommended levels in persons with diabetes reduces cardiovascular events, and reduces office visits and hospitalizations to non-comorbid levels. Hypertension. 2009;54:e55. Abstract P126
   Google Scholar
• . Chobanian AV, Bakris GL, Black HR, ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252
   PubMed Web of Science ®Google Scholar
• . Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19): 2486–2497
   PubMed Web of Science ®Google Scholar
• . Schmittdiel JA, Uratsu CS, Karter AJ, . Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008;23(5): 588–594
   PubMed Web of Science ®Google Scholar
• . Grant RW, Cagliero E, Dubey AK, . Clinical inertia in the management of type 2 diabetes metabolic risk factors. Diabet Med. 2004;21(2):150–155
   PubMedGoogle Scholar
• . Greving JP, Denig P, de Zeeuw D, Bilo HJ, Haaijer—Ruskamp FM. Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998–2004: a longitudinal observational study. Cardiovasc Diabetol. 2007;6:25
   PubMedGoogle Scholar
• . McKeage K, Siddiqui MA. Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. Am J Cardiovasc Drugs. 2008;8(1):51–67
   PubMed Web of Science ®Google Scholar
• . Zamorano J, Erdine S, Lopez AP, ; CRUCIAL Investigators. Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med. 2010;122(2):7–15
   PubMed Web of Science ®Google Scholar
• . Zamorano J, Erdine S, Pavia A, . Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin. 2011;27(4):821–833
   PubMed Web of Science ®Google Scholar
• . World Medical Association. (2008) The World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th World Medical Association General Assembly, Helsinki, Finland, June 1964. Last amended by the World Medical Association General Assembly in Seoul, Korea, October 2008. http://www.wma.net/en/30publications/10policies/b3/. Accessed October 11, 2010
   Google Scholar
• . Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553
   PubMed Web of Science ®Google Scholar
• . Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847
   PubMed Web of Science ®Google Scholar
• . Richard Hobbs FD, Gensini G, John Mancini GB, ; JEWEL Study Group. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil. 2009;16(4):472–480
   PubMedGoogle Scholar
• . Flack JM, Victor R, Watson K, . Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc. 2008;83(1):35–45
   PubMed Web of Science ®Google Scholar
• . Jenssen TG, Aguilar—Salinas CA, Hobbs R, . Control of blood pressure and low-density lipoprotein cholesterol with single-pill amlodipine/atorvastatin: a pooled analysis of patients with and without diabetes. Presented at: 44th Annual Meeting of European Association for the Study of Diabetes; September 7–11, 2008; Rome, Italy
   Google Scholar
• . Erdine S, Ro YM, Tse HF, . Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens. 2009;23(3):196–210
   PubMed Web of Science ®Google Scholar
• . LaSalle J, Hershon K, Berman L, Gibson E, Gillen D, Maroni J. Utility of amlodipine/atorvastatin single-pill therapy in patients with diabetes mellitus: results from the Gemini study. Presented at: 40th Annual Meeting of the European Association for the Study of Diabetes; September 5–9, 2004; Munich, Germany
   Google Scholar
• . Aguilar—Salinas CA, Ro YM, Tse HF, . Clinical utility of single-pill amlodipine/atorvastatin for the attainment of blood pressure and lipid goals in patients of diverse ethnicity with diabetes: results from the Gemini AALA study. Presented at: 43rd Annual Meeting of the European Association for the Study of Diabetes; September 18–21, 2007; Amsterdam, The Netherlands
   Google Scholar
• . Ferdinand KC, Flack JM, Saunders E, . Amlodipine/atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2009;11(10):585–593
   PubMedGoogle Scholar
• . Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens. 2005;7(5):264–273
   Google Scholar
• . Grundy SM, Cleeman JI, Merz CN, . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239
   PubMed Web of Science ®Google Scholar
• . Sever P, Dahlöf B, Poulter N, ; ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;27(24):2982–2988
   PubMed Web of Science ®Google Scholar
• . Howard BV, Roman MJ, Devereux RB, . Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA. 2008;299(14):1678–1689
   PubMed Web of Science ®Google Scholar